CPRX - Catalyst Pharmaceutical - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.745B

Cash

310.4M

Avg Qtr Burn

N/A

Short % of Float

5.26%

Insider Ownership

6.21%

Institutional Own.

83.14%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FIRDAPSE®(Amifampridine) Details Lamber-Eaton myasthenic syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AGAMREE® (Vamorolone) Details Duchenne muscular dystrophy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FYCOMPA Details Epilepsy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FIRDAPSE®(Amifampridine) Details Autoimmune disease, Lamber-Eaton myasthenic syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FIRDAPSE® (Amifampridine) Details Autoimmune disease, Neuromuscular disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.